Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Zanubrutinib in combination with R-CHOP for previously untreated mcd type of Diffuse large b-cell lymphoma (DLBCL).

View Full Paper
Ask AI
Bookmark
Share

Authors

YLYing LuLSLihong ShouJJJie Jin

Discussion

Loading...

Member takes

Overview

Randomised trial shows 95% progression-free survival in untreated DLBCL patients with MCD subtype, suggesting zanubrutinib is a promising therapy.

Key Points

  • Zanubrutinib plus R-CHOP achieved a 95% progression-free survival at two years in MCD DLBCL patients.
  • The overall response rate was reported at 92.5%, with 87.5% achieving complete remission after treatment.
  • This prospective analysis assessed efficacy and safety in patients with MCD subtype DLBCL using standard chemotherapy and zanubrutinib.
  • The treatment showed high efficacy, but neutropenia was a notable adverse event in incidence during therapy.

Cite This Study

Lu et al. (2025) studied this question.

synapsesocial.com/papers/69362f604fa91c937236dd7chttps://doi.org/10.1182/blood-2025-1907
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Efficacy and safety of zanubrutinib combined with chemotherapy in the treatment of relapsed/refractory diffuse large B-cell lymphoma2025
  2. 2Efficacy and Safety of Zanubrutinib Combined with Rituximab and High-Dose Methotrexate in the Treatment of Central Nervous System Diffuse Large B-Cell Lymphoma2025
  3. 3Zanubrutinib plus R-CHOP versus R-CHOP as first-line therapy in double-expressor DLBCL: A multicenter, propensity score matched retrospective study2025
  4. 4A phase 2 study of zanubrutinib in combination with rituximab and lenalidomide in de novo diffuse large B-cell lymphoma2025 · 5 citations
  5. 5Efficacy and safety of zanubrutinib combined with anti-CD20 monoclonal antibody-based regimens as first-line therapy in high-risk follicular lymphoma and marginal zone lymphoma: A single-arm retrospective study2025